Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Osteocalcin Antikörper (N-Term)

BGLAP Reaktivität: Human WB, IHC (p), EIA Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN357367
  • Target Alle Osteocalcin (BGLAP) Antikörper anzeigen
    Osteocalcin (BGLAP)
    Bindungsspezifität
    • 15
    • 10
    • 8
    • 8
    • 8
    • 7
    • 7
    • 6
    • 6
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 9-39, N-Term
    Reaktivität
    • 94
    • 43
    • 21
    • 20
    • 19
    • 15
    • 15
    • 10
    • 8
    • 7
    • 4
    • 1
    • 1
    • 1
    Human
    Wirt
    • 85
    • 32
    • 2
    • 2
    • 1
    Kaninchen
    Klonalität
    • 89
    • 33
    Polyklonal
    Konjugat
    • 73
    • 12
    • 10
    • 7
    • 5
    • 4
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser Osteocalcin Antikörper ist unkonjugiert
    Applikation
    • 90
    • 66
    • 44
    • 15
    • 14
    • 14
    • 14
    • 9
    • 8
    • 8
    • 8
    • 6
    • 5
    • 2
    • 2
    • 2
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)
    Spezifität
    This antibody detects Osteocalcin at N-term.
    Kreuzreaktivität (Details)
    Species reactivity (tested):Human.
    Aufreinigung
    Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
    Immunogen
    Synthetic peptide KLH conjugated between 9~39 amino acids from the N-terminal region of Human Osteocalcin.
    Isotyp
    Ig Fraction
    Top Product
    Discover our top product BGLAP Primärantikörper
  • Applikationshinweise
    ELISA: 1/1,000. Western blot: 1/100-1/500. Immunohistochemistry: 1/50-1/100.
    Other applications not tested.
    Optimal dilutions are dependent on conditions and should be determined by the user.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    0.25 mg/mL
    Buffer
    PBS with 0.09 % (W/V) Sodium Azide as preservative
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Handhabung
    Avoid repeated freezing and thawing.
    Lagerung
    4 °C/-20 °C
    Informationen zur Lagerung
    Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
  • Target
    Osteocalcin (BGLAP)
    Andere Bezeichnung
    Osteocalcin (BGLAP Produkte)
    Synonyme
    BGP antikoerper, OC antikoerper, OCN antikoerper, Bglap1 antikoerper, Bglap2 antikoerper, OG1 antikoerper, mOC-A antikoerper, Bgp antikoerper, Bgpr antikoerper, Bgpra antikoerper, bgp antikoerper, LOC792433 antikoerper, ocn antikoerper, GLA antikoerper, BGLAP antikoerper, PMF1 antikoerper, bone gamma-carboxyglutamate protein antikoerper, bone gamma carboxyglutamate protein antikoerper, bone gamma-carboxyglutamate protein S homeolog antikoerper, bone gamma-carboxyglutamate (gla) protein antikoerper, osteocalcin antikoerper, polyamine-modulated factor 1 antikoerper, BGLAP antikoerper, Bglap antikoerper, bglap.S antikoerper, bglap antikoerper, ocn antikoerper, LOC100529177 antikoerper, LOC100146589 antikoerper
    Hintergrund
    Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2 % of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.Synonyms: BGLAP, Bone Gla protein, Gamma-carboxyglutamic acid-containing protein
    Molekulargewicht
    10962 Da
    Gen-ID
    632
    NCBI Accession
    NP_954642
    UniProt
    P02818
Sie sind hier:
Kundenservice